Sodium-glucose cotransporter 2 inhibitor use: A pharmaco-ergonomic qualification tool

Abstract

Pharmaco-ergonomics implies tailoring the drug therapy to an individual patient's requirement(s). The development of sodium-glucose cotransporter 2 inhibitor (SGLT2-i) agents has impelled multiple clinical considerations, in the management of type-2 diabetes. This paper attempts to summarize the pharmaco-ergonomic considerations for these agents, in the form of an SGLT2-i qualification tool, based on a clinical score. This tool may serve as a simple and inexpensive practical guide, to optimize the risk-benefit considerations for SGLT2-i agents.

Keywords

• Pharmaco-ergonomics
• sodium-glucose cotransporter 2 inhibitor clinical score
• sodium-glucose cotransporter 2 inhibitor qualification tool